<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03684785</url>
  </required_header>
  <id_info>
    <org_study_id>AST-008-102</org_study_id>
    <nct_id>NCT03684785</nct_id>
  </id_info>
  <brief_title>Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors</brief_title>
  <official_title>Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors: A Phase 1b/2 Study of Cavrotolimod Combined With Pembrolizumab or Cemiplimab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exicure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exicure, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b/2, open-label, two-part, multicenter trial designed to evaluate the&#xD;
      safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of&#xD;
      intratumoral cavrotolimod injections alone and in combination with intravenous pembrolizumab&#xD;
      or cemiplimab in patients with Merkel Cell Carcinoma, cutaneous squamous cell carcinoma, and&#xD;
      advanced solid tumors.&#xD;
&#xD;
      Phase 1b of this trial is a 3+3 dose escalation study evaluating escalating or intermediate&#xD;
      dose levels of cavrotolimod given with a fixed dose of pembrolizumab.&#xD;
&#xD;
      The Phase 2 dose expansion part of the study will consist of two primary cohorts of patients:&#xD;
      Merkel cell carcinoma and cutaneous squamous cell carcinoma. Patients in the Merkel Cell&#xD;
      Carcinoma cohort will receive IT cavrotolimod combined with a fixed, standard dose of&#xD;
      pembrolizumab while the Cutaneous Squamous Cell Carcinoma cohort will receive IT cavrotolimod&#xD;
      combined with a fixed, standard dose of cemiplimab. The Phase 2 dose expansion is designed to&#xD;
      provide a preliminary estimate of efficacy in patients that have progressed on an&#xD;
      anti-PD-(L)1 CPI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in 2 phases. Phase 1 evaluates cavrotolimod given in combination&#xD;
      with pembrolizumab in patients with advanced solid tumors in a classical 3+3 dose escalation&#xD;
      design, with up to five ascending dose cohorts of cavrotolimod and enrollment of at least 3&#xD;
      patients per cohort to identify an RP2D. Patients will be dosed twice with cavrotolimod as a&#xD;
      monotherapy before adding pembrolizumab, which will be added starting at the second cycle.&#xD;
      Once the MTD or highest escalation cohort has been reached, or notable efficacy has been&#xD;
      observed at a given dose level, and a decision as to a RP2D has been made, a two 2-stage&#xD;
      expansion cohort design will be initiated.&#xD;
&#xD;
      Phase 2 will evaluate the RP2D of cavrotolimod given in combination with pembrolizumab or&#xD;
      cemiplimab in two expansion cohorts following a modified Simon 2-stage optimal design&#xD;
      comprised of patients with Merkel cell carcinoma or cutaneous squamous cell carcinoma. who&#xD;
      previously received and have progressed on an anti-PD-(L)1 CPI. Patients in the Merkel Cell&#xD;
      Carcinoma cohort will receive IT cavrotolimod combined with a fixed, standard dose of&#xD;
      pembrolizumab while the Cutaneous Squamous Cell Carcinoma cohort will receive IT cavrotolimod&#xD;
      combined with a fixed, standard dose of cemiplimab.&#xD;
&#xD;
      Phase 2 will include an exploratory expansion cohort to evaluate cavrotolimod in combination&#xD;
      with pembrolizumab in patients with other advanced solid tumors, including melanoma, who have&#xD;
      progressed on anti-PD-(L)1 therapy.&#xD;
&#xD;
      Exploratory expansion cohorts will evaluate patients with melanoma and additional patients&#xD;
      with Merkel Cell Carcinoma who do not meet criteria for enrollment in the primary Merkel Cell&#xD;
      Carcinoma cohort. In addition, two exploratory cohorts have been added to evaluate patients&#xD;
      with advanced solid tumors and no superficial tumor accessible for IT injection using&#xD;
      subcutaneously administered cavrotolimod or IT injection into liver metastases.&#xD;
&#xD;
      A cohort of up to 10 evaluable patients with locally advanced or metastatic solid tumors with&#xD;
      no cutaneous, subcutaneous, or accessible nodal tumor lesions available for IT injection may&#xD;
      be enrolled (inclusion criterion #4). The inclusion/exclusion criteria for this exploratory&#xD;
      cohort will otherwise be the same as those used for the Phase 2 dose expansion cohorts except&#xD;
      these patients will not be required to have a lesion accessible for biopsy (inclusion&#xD;
      criterion #5). Patients will be dosed with cavrotolimod subcutaneously at a dose not to&#xD;
      exceed the recommended Phase 2 dose, 32 mg, in combination with pembrolizumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events of cavrotolimod alone and in combination with pembrolizumab or cemiplimab</measure>
    <time_frame>Study day 36</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recommended Phase 2 dose</measure>
    <time_frame>12 months</time_frame>
    <description>To recommend a dose of cavrotolimod and combination regimen for further development</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) per RECIST v1.1</measure>
    <time_frame>24 months</time_frame>
    <description>ORR to be calculated overall and by cohort/subgroup using RECIST v1.1. Subgroups will be defined for the efficacy analyses based on prior exposure and response to immune checkpoint inhibitors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure changes in correlative biomarkers including tumor-infiltrating lymphocytes, PD-L1 and other checkpoint expression at baseline, after cavrotolimod monotherapy, and after combination therapy of both cavrotolimod and pembrolizumab or cemiplimab.</measure>
    <time_frame>Study day 36</time_frame>
    <description>IHC on FFPE biopsies will be used to assess markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure changes in gene expression profiles at baseline, after cavrotolimod monotherapy, and after combination therapy of both cavrotolimod and pembrolizumab or cemiplimab.</measure>
    <time_frame>Study day 36</time_frame>
    <description>Selected gene-expression profiling on gene expression will be performed with nCounter (NanoString Technologies).</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Advanced or Metastatic Merkel Cell Carcinoma</condition>
  <condition>Advanced or Metastatic Cutaneous Squamous Cell Carcinoma</condition>
  <condition>Advanced or Metastatic Melanoma</condition>
  <condition>Advanced or Metastatic Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Advanced or Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Phase 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the recommended Phase 2 dose of cavrotolimod in combination with pembrolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Phase 2; Merkel cell carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with advanced Merkel cell carcinoma that have progressed on an anti-PD-1 / anti-PD-L1 therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Phase 2, cutaneous squamous cell carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and preliminary efficacy of cavrotolimod and cemiplimab in patients with advanced cutaneous squamous cell carcinoma that have progressed on an anti-PD-1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exploratory Phase 2, Merkel cell carinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with advanced Merkel cell carcinoma that have progressed on anti-PD-1 / anti-PD-L1 therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exploratory Phase 2, Subcutaneous Dosing Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with no cutaneous, subcutaneous, or accessible nodal tumor lesions amenable that have progressed on anti-PD-1 / anti-PD-L1 therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exploratory Phase 2, Melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with locally Advanced or Metastatic Melanoma that have progressed on anti-PD-1 / anti-PD-L1 therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exploratory Phase 2, Liver Lesion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with metastatic solid tumors with liver metastases that have progressed on anti-PD-1 / anti-PD-L1 therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cavrotolimod</intervention_name>
    <description>Intratumorally dosed cavrotolimod.</description>
    <arm_group_label>Dose Escalation Phase 1b</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2, cutaneous squamous cell carcinoma</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2; Merkel cell carcinoma</arm_group_label>
    <arm_group_label>Exploratory Phase 2, Liver Lesion</arm_group_label>
    <arm_group_label>Exploratory Phase 2, Melanoma</arm_group_label>
    <arm_group_label>Exploratory Phase 2, Merkel cell carinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab dosing as per the US prescribing information.</description>
    <arm_group_label>Dose Escalation Phase 1b</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2; Merkel cell carcinoma</arm_group_label>
    <arm_group_label>Exploratory Phase 2, Liver Lesion</arm_group_label>
    <arm_group_label>Exploratory Phase 2, Melanoma</arm_group_label>
    <arm_group_label>Exploratory Phase 2, Merkel cell carinoma</arm_group_label>
    <arm_group_label>Exploratory Phase 2, Subcutaneous Dosing Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cemiplimab</intervention_name>
    <description>Cemiplimab dosing as per the US prescribing information.</description>
    <arm_group_label>Dose Expansion Phase 2, cutaneous squamous cell carcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cavrotolimod</intervention_name>
    <description>Subcutaneously dosed cavrotolimod</description>
    <arm_group_label>Exploratory Phase 2, Subcutaneous Dosing Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent.&#xD;
&#xD;
          2. Male or female ≥18 years of age.&#xD;
&#xD;
          3. Must have an advanced inoperable histologically diagnosed solid tumor.&#xD;
&#xD;
               -  Phase 2 Merkel Cell Carcinoma Dose Expansion Cohort: locally advanced or&#xD;
                  metastatic Merkel cell caricinoma&#xD;
&#xD;
               -  Phase 2 Cutaneous Squamous Cell Carcinoma Dose Expansion Cohort: locally advanced&#xD;
                  or metastatic cutaneous squamous cell carcinoma&#xD;
&#xD;
               -  Phase 2 Merkel Cell Carcinoma Exploratory Expansion Cohort: locally advanced or&#xD;
                  metastatic Merkel cell carcinoma&#xD;
&#xD;
               -  Phase 2 Melanoma Exploratory Expansion Cohort: Locally advanced or metastatic&#xD;
                  melanoma&#xD;
&#xD;
               -  Phase 2 Subcutaneous Dosing Exploratory Cohort: Locally advanced or metastatic&#xD;
                  solid tumors&#xD;
&#xD;
               -  Phase 2 Liver Lesion Exploratory Cohort: metastatic solid tumors with liver&#xD;
                  metastases&#xD;
&#xD;
          4. Phase 1b, Phase 2 Merkel Cell Carcinoma Dose Expansion Cohort, Phase 2 Cutaneous&#xD;
             Squamous Cell Carcinoma Dose Expansion Cohort, Phase 2 Merkel Cell Carcinoma&#xD;
             Exploratory Expansion Cohort, Phase 2 Melanoma Exploratory Expansion Cohort:&#xD;
&#xD;
             At least one tumor lesion amenable to repeated IT injection via palpation or&#xD;
             ultrasound. Injection of deep visceral lesions is not permitted.&#xD;
&#xD;
             Patients enrolled in subcutaneous dosing cohort do not need lesions amenable to&#xD;
             subcutaneous dosing.&#xD;
&#xD;
          5. Phase 1b and Phase 2 Melanoma Exploratory Expansion Cohort:&#xD;
&#xD;
             Agrees to provide a newly obtained biopsy of one or two lesions, and agrees to repeat&#xD;
             biopsies, if applicable.&#xD;
&#xD;
          6. Phase 1b:&#xD;
&#xD;
             In the investigator's opinion the patient may derive clinical benefit from the&#xD;
             treatment or is ineligible for a particular form of standard therapy due to&#xD;
             tolerability, or the patient failed one or more established standard medical&#xD;
             anti-cancer therapies. Exposure to anti-PD-(L)1 or anti-CTLA-4 antibody CPIs is&#xD;
             permitted but not required.&#xD;
&#xD;
             Phase 2 Merkel Cell Carcinoma Dose Expansion Cohort:&#xD;
&#xD;
             i. At least a minimum number of cycles of avelumab, nivolumab, or pembrolizumab. Prior&#xD;
             anti-CTLA-4 antibody therapy, including as most recent preceding therapy in&#xD;
             combination with avelumab or pembrolizumab, is permitted but not required.&#xD;
&#xD;
             ii. Confirmed progressive disease during treatment with avelumab or pembrolizumab&#xD;
             therapy,&#xD;
&#xD;
             Phase 2 Cutaneous Squamous Cell Carcinoma Dose Expansion Cohort&#xD;
&#xD;
             i. At least a minimum number of cycles of cemiplimab, nivolumab, or pembrolizumab.&#xD;
             Prior ipilimumab therapy, including as most recent preceding therapy in combination&#xD;
             with cemiplimab, nivolumab, or pembrolizumab, is permitted but not required.&#xD;
&#xD;
             ii. Confirmed progressive disease on cemiplimab or pembrolizumab therapy&#xD;
&#xD;
             Phase 2 MCC and Melanoma Exploratory Expansion Cohort and Phase 2 Subcutaneous Dosing&#xD;
             Exploratory Expansion Cohort:&#xD;
&#xD;
             i. Treatment duration with anti-PD-(L)1 antibody ≥8 weeks as the most recent preceding&#xD;
             therapy prior to being enrolled in this study with confirmed progression. Anti-PD-(L)1&#xD;
             was administrated for metastatic or locally advanced Merkel Cell Carcinoma or&#xD;
             melanoma. Prior ipilimumab therapy, including as most recent therapy in combination&#xD;
             with anti-PD-(L)1 therapy, is permitted but not required.&#xD;
&#xD;
             ii. Confirmed progressive disease on anti-PD-(L)1 antibody therapy&#xD;
&#xD;
          7. Phase 1b and Phase 2 Melanoma Exploratory Expansion Cohort:&#xD;
&#xD;
             Evaluable disease per RECIST 1.1 with at least two target lesions as defined by RECIST&#xD;
             1.1. Both injectable and non-injectable target lesions should be chosen for efficacy&#xD;
             evaluation.&#xD;
&#xD;
          8. For the Phase 2 expansion portions of the study, a maximum of 4 prior lines of&#xD;
             systemic treatment for locally advanced or metastatic disease.&#xD;
&#xD;
               -  Phase 2 Merkel Cell Carcinoma and Melanoma Exploratory Expansion Cohorts and&#xD;
                  Phase 2 Subcutaneous Dosing Exploratory Cohort&#xD;
&#xD;
          9. For female patients of childbearing potential, defined as females who 1) have not&#xD;
             undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy or 2)&#xD;
             have not been postmenopausal for at least 12 consecutive months [i.e., have had menses&#xD;
             at any time during the preceding 12 consecutive months]):&#xD;
&#xD;
             • Willing to use one of the following effective methods of contraception for at least&#xD;
             30 days before administration of cavrotolimod, during treatment with cavrotolimod,&#xD;
             pembrolizumab, or cemiplimab, and for at least four months after the last dose of&#xD;
             cavrotolimod, pembrolizumab, or cemiplimab:&#xD;
&#xD;
             i. Total abstinence from sexual intercourse with a partner that may result in&#xD;
             pregnancy&#xD;
&#xD;
             ii. Hormonal contraception (oral, parenteral, or transdermal) used for at least 3&#xD;
             consecutive months prior to the first dose of cavrotolimod&#xD;
&#xD;
             iii. Intrauterine contraceptive device&#xD;
&#xD;
             iiii. Barrier contraception (i.e., condom, cap, diaphragm, or sponge with spermicide)&#xD;
&#xD;
             For male patients who have not had a vasectomy:&#xD;
&#xD;
             • Willing to use one of the following effective methods of contraception for at least&#xD;
             30 days before administration of cavrotolimod, during treatment with cavrotolimod,&#xD;
             pembrolizumab, or cemiplimab, and for at least four months after the last dose of&#xD;
             cavrotolimod, pembrolizumab, or cemiplimab:&#xD;
&#xD;
             i. Total abstinence from sexual intercourse with a female partner of childbearing&#xD;
             potential&#xD;
&#xD;
             ii. Use by female partner of hormonal contraception (oral, parenteral, or transdermal)&#xD;
             for at least 3 consecutive months prior to the first dose of cavrotolimod&#xD;
&#xD;
             iii. Use by female partner of intrauterine contraceptive device&#xD;
&#xD;
             iiii. Barrier contraception (i.e., condom, cap, diaphragm, or sponge with spermicide)&#xD;
&#xD;
         10. Regarding history of CPI-related adverse events:&#xD;
&#xD;
             i. Resolution of CPI-related AEs (including irAEs) to G0-1 and no corticosteroids for&#xD;
             the amelioration of those irAEs for at least 4 weeks prior to the first dose of&#xD;
             cavrotolimod. Controlled hypothyroidism and controlled adrenal insufficiency are&#xD;
             exceptions to this criterion, provided doses do not exceed the threshold described in&#xD;
             exclusion criterion #13.&#xD;
&#xD;
             ii. No history of CTCAE G4 irAEs from CPI. iii. No history of CTCAE G3 irAEs from CPI.&#xD;
             Patients with a history of CTCAE G3 irAEs from CPI requiring steroid treatment for no&#xD;
             greater than 12 weeks may be considered at the discretion of the Investigator if&#xD;
             supported by an assessment of risk-benefit and after discussion with the Medical&#xD;
             Monitor.&#xD;
&#xD;
         11. Adequate organ function.&#xD;
&#xD;
         12. Able and willing to comply with the protocol and the restrictions and assessments&#xD;
             therein.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Small molecule or tyrosine kinase inhibitor within 2 weeks or 5 half-lives (whichever&#xD;
             is longer) prior to the first dose of cavrotolimod, chemotherapy or biological cancer&#xD;
             therapy within 3 weeks prior to the first dose of cavrotolimod, nitrosourea, or&#xD;
             radioisotope within 6 weeks prior to first dose of cavrotolimod, or non-recovery to&#xD;
             CTCAE G1 or better from the AEs due to cancer therapeutics administered more than 4&#xD;
             weeks earlier.&#xD;
&#xD;
          2. Known hypersensitivity to any phosphorothioate oligonucleotide, or previous exposure&#xD;
             to a TLR9 agonist drug.&#xD;
&#xD;
          3. Previous severe hypersensitivity reaction to treatment with pembrolizumab, cemiplimab&#xD;
             or another anti-PD-(L)1 monoclonal antibody.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) &gt;1.&#xD;
&#xD;
          5. Symptomatic ascites or pleural effusion. A patient with these conditions who has&#xD;
             received treatment such as therapeutic thoracentesis or paracentesis and is clinically&#xD;
             stable, defined as not requiring repeat drainage procedure within 2 weeks, may be&#xD;
             considered after discussion with the Medical Monitor.&#xD;
&#xD;
          6. Known active CNS metastases and/or carcinomatous meningitis. Patients with previously&#xD;
             treated brain metastases may participate provided they are clinically stable for at&#xD;
             least 4 weeks prior to the first dose of cavrotolimod, have no evidence of new or&#xD;
             enlarging brain metastases and are off steroids for at least 14 days prior to the&#xD;
             first dose of cavrotolimod.&#xD;
&#xD;
          7. Known history of a hematologic malignancy, malignant primary brain tumor or malignant&#xD;
             sarcoma, or of another malignant primary solid tumor (other than that under study),&#xD;
             with the following exceptions: 1) patients who have undergone potentially curative&#xD;
             therapy with no evidence of that disease for 3 years prior to the first dose of&#xD;
             cavrotolimod; 2) patients who underwent successful definitive resection of basal cell&#xD;
             carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the&#xD;
             skin, in situ cervical cancer, or other in situ cancers; 3) stable chronic lymphocytic&#xD;
             leukemia not requiring treatment within 3 years prior to the first dose of&#xD;
             cavrotolimod.&#xD;
&#xD;
          8. Significant autoimmune disease that requires or required systemic steroids or&#xD;
             immunosuppressive agents within the last year. The following are not exclusionary: 1)&#xD;
             vitiligo, resolved asthma/atopy, and limited eczema; 2) conidtions requiring&#xD;
             intermittent use of bronchodilators or local steroid injections; 3) hypothyroidism or&#xD;
             adrenal insufficiency that is stable on hormone replacement; or 4) irAEs related to&#xD;
             checkpoint inhibitor therapy, provided inclusion criterion #10 and exclusion criterion&#xD;
             #11 are met.&#xD;
&#xD;
          9. Use of systemic corticosteroids to treat inflammatory or autoimmune symptoms within 15&#xD;
             days or other immunosuppressive drugs within 30 days prior to the first dose of&#xD;
             cavrotolimod. Inhaled and topical corticosteroids are permitted. Up to 10 mg/day&#xD;
             prednisone or equivalent is permitted for hypothyroidism or adrenal insufficiency.&#xD;
&#xD;
         10. Received an investigational product or been treated with an investigational device&#xD;
             within 30 days prior to the first dose of cavrotolimod or will start any other&#xD;
             investigational product or device study within 30 days after last study drug&#xD;
             administration.&#xD;
&#xD;
         11. History or clinical evidence of any surgical or medical condition which the&#xD;
             Investigator judges as likely to interfere with the results of the study or pose an&#xD;
             additional risk in participating e.g., rapidly progressive or uncontrolled disease&#xD;
             involving a major organ system-vascular, cardiac, pulmonary, gastrointestinal,&#xD;
             gynecologic, hematologic, neurologic, neoplastic, renal, endocrine or an&#xD;
             immunodeficiency, or clinically significant active psychiatric or abuse disorders.&#xD;
&#xD;
         12. Pregnant or breastfeeding or expecting to conceive or father children within the&#xD;
             projected duration of the study through 4 months after the last dose of cavrotolimod,&#xD;
             pembrolizumab, or cemiplimab.&#xD;
&#xD;
         13. Allergy or intolerance preventing use of H1 blockers (e.g., diphenhydramine,&#xD;
             cetirizine) and H2 blockers (e.g., famotidine) used as antihistamine premedication&#xD;
             prior to cavrotolimod injection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Exicure Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Exicure, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emil deGoma, MD</last_name>
    <phone>1-617-762-0601</phone>
    <email>edegoma@exicuretx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Vasquez</last_name>
      <phone>520-694-1053</phone>
      <email>jrv3@email.arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Gao, MD</last_name>
      <phone>501-265-9307</phone>
      <email>lingg3@hs.uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94185</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari Oglesby</last_name>
      <email>Arielle.Oglesby@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute / Providence St. John's Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandra Dubinchik</last_name>
      <phone>310-582-7455</phone>
      <email>aleksandra.dubinchik@providence.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Nuanes</last_name>
      <phone>720-848-8845</phone>
      <email>victoria.nuanes@CUAnschutz.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western States Cancer Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Fonseca, CCRC</last_name>
      <phone>305-243-3360</phone>
      <email>mfonseca4@miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-695-1301</phone>
      <email>cancertrials@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mimi McKay, RN BSN</last_name>
      <phone>319-467-5831</phone>
      <email>mariel-mckay@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaspreet Grewal, MD, PhD, MPH</last_name>
      <email>DERM-NCIResearch@nortonhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Rowan</last_name>
      <email>JenniferM_Rowan@DFCI.HARVARD.EDU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Puspanjali Bhatta, CCRP</last_name>
      <phone>317-286-0896</phone>
      <email>pbhatta@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Wierzbicki</last_name>
      <phone>603-650-5475</phone>
      <email>Rachel.M.Wierzbicki@hitchcock.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valley - Mount Sinai Comprehensive Cancer Center</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sequoia Young</last_name>
      <email>SYOUNG3@valleyhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Perlmutter Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Pollak</last_name>
      <phone>917-705-7978</phone>
      <email>Sarah.Pollak@nyulangone.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciara Kelly, MD BCh BAO</last_name>
      <phone>646-888-4312</phone>
      <email>kellyc1@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol A Wiggs</last_name>
      <email>carolann.wiggs@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Fuhrman, CRC</last_name>
      <phone>513-584-8162</phone>
      <email>fuhrmaba@ucmail.uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>800-293-5066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Oliveira</last_name>
      <email>oliveirl@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center / Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Rose, RN</last_name>
      <phone>412-647-8587</phone>
      <email>kennaj@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Wright</last_name>
      <email>jennifer.wright2@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srisuda (Mou) Lecagoonporn</last_name>
      <email>slecagoo@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington- Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Tsuji</last_name>
      <phone>206-606-1645</phone>
      <email>jktsuji@seattlecca.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia Cancer Institute</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Ross</last_name>
      <phone>304-581-1158</phone>
      <email>carla.ross@hsc.wvu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.exicuretx.com</url>
    <description>Exicure homepage</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced or Metastatic Merkel Cell Carcinoma</keyword>
  <keyword>Advanced or Metastatic Cutaneous Squamous Cell Carcinoma</keyword>
  <keyword>Advanced or Metastatic Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>Advanced or Metastatic Melanoma</keyword>
  <keyword>Advanced or Metastatic Solid Tumors</keyword>
  <keyword>Head and Neck</keyword>
  <keyword>Squamous Cell Carinoma</keyword>
  <keyword>Cutaneous Squamous Cell Carcinoma</keyword>
  <keyword>Merkel Cell Carcinoma</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Skin Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in the article, after de-identification (text, tables, figures, and appendices) will be shared to researchers who provide a methodologically sound proposal and sign a data access agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication.</ipd_time_frame>
    <ipd_access_criteria>Access will be considered to researchers who provide a methodologically sound proposal. Analysis must achieve the aims outlined in the approved proposal. Proposals should be directed to edegoma@exicuretx.com. To gain access, data requestors will need to sign a data access agreement. Data are available for 36 months following article publication.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

